MCL1 and acute myeloid leukemia: Given the observed and reported24,25 sensitivity of AML cells to MCL-1 inhibition in vitro, the activity of ABBV-467 was evaluated as both monotherapy and with standard-of-care (SOC) agents in AML xenografts in vivo.